CA125-related Measures of Tumor Kinetics and Outcome of Patients with Recurrent Ovarian Cancer Receiving Chemotherapy: A Retrospective Evaluation

被引：5
作者：
Colloca, Giuseppe [1 ]
Venturino, Antonella [1 ]
Addamo, Gianfranco [1 ]
Coccorullo, Zaira [1 ]
Ratti, Riccardo [1 ]
Caltabiano, Graziano [1 ]
Guarneri, Domenico [1 ]
机构：
[1] G Borea Hosp, Div Med Oncol, San Remo, Italy
来源：
JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 43卷 / 12期
关键词：
Ovarian cancer; tumor growth rate; chemotherapy; surrogate end point; PEGYLATED LIPOSOMAL DOXORUBICIN; RESPONSE CRITERIA; CA125; RESPONSE; DOUBLING TIME; GROWTH-RATE; THERAPY;
D O I：
10.1093/jjco/hyt139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Defining the reliability of cancer antigen-125-related kinetics criteria versus Gynecologic Cancer Inter Group criteria in predicting the tumor outcome after chemotherapy in patients with recurrent ovarian cancer. A retrospective monoinstitutional assessment of CA125-related versus Gynecologic Cancer Inter Group-related parameters was performed after cytotoxic chemotherapy in patients with metastatic ovarian cancer treated from 2006 to 2011. A correlation analysis between the response and progression measurements has been performed, and the outcome has been reported. Among 42 eligible patients, tumor response and progression calculated by CA125 kinetics, with tumor response at 8 weeks and specific growth rate at progression, exhibited a significant correlation with progression-free and overall survival, similar to tumor response and progression by Gynecologic Cancer Inter Group criteria. The tumor response at 8 weeks higher than 1.77 appears to be a good surrogate of clinical response, whereas the definition of progression when CA125 increases above a value double than the nadir suggests a similar performance of growth rate at progression versus Gynecologic Cancer Inter Group criteria and warrants further investigation.
引用
收藏
页码：1203 / 1209
页数：7
相关论文
共 14 条
  • [1] Cancer of the ovary
    Cannistra, SA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) : 2519 - 2529
  • [2] Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients
    Coleman, Robert L.
    Gordon, Alan
    Barter, James
    Sun, Steven
    Rackoff, Dwayne
    Herzog, Thomas J.
    [J]. ONCOLOGIST, 2007, 12 (01) : 72 - 78
  • [3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [4] Estimates of cancer incidence and mortality in Europe in 2008
    Ferlay, J.
    Parkin, D. M.
    Steliarova-Foucher, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (04) : 765 - 781
  • [5] Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer
    Ferrandina, Gabriella
    Ludovisi, Manuela
    Corrado, Giacomo
    Carone, Vito
    Petrillo, Marco
    Scambia, Giovanni
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 109 (02) : 187 - 193
  • [6] CA125 response: Can it replace the traditional response criteria in ovarian cancer?
    Guppy, AE
    Rustin, GJS
    [J]. ONCOLOGIST, 2002, 7 (05) : 437 - 443
  • [7] An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy
    Liu, Ping-Yu
    Alberts, David S.
    Monk, Bradley J.
    Brady, Mark
    Moon, James
    Markman, Maurie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) : 3615 - 3620
  • [8] Objective assessment of tumour response to therapy based on tumour growth kinetics
    Mehrara, E.
    Forssell-Aronsson, E.
    Bernhardt, P.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (05) : 682 - 686
  • [9] Specific growth rate versus doubling time for quantitative characterization of tumor growth rate
    Mehrara, Esmaeil
    Forssell-Aronsson, Eva
    Ahlman, Hakan
    Bernhardt, Peter
    [J]. CANCER RESEARCH, 2007, 67 (08) : 3970 - 3975
  • [10] Quantitative analysis of tumor growth rate and changes in tumor marker level: Specific growth rate versus doubling time
    Mehrara, Esmaeil
    Forssell-Aronsson, Eva
    Ahlman, Hakan
    Bernhardt, Peter
    [J]. ACTA ONCOLOGICA, 2009, 48 (04) : 591 - 597
12